<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04688905</url>
  </required_header>
  <id_info>
    <org_study_id>283/20</org_study_id>
    <nct_id>NCT04688905</nct_id>
  </id_info>
  <brief_title>Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)</brief_title>
  <official_title>Diagnosestellung Der Herzinsuffizienz Mit Erhaltener Ejektionsfraktion Bei Patienten Mit Unklarer Belastungsdyspnoe - Validierung Gegen Den Invasiven Goldstandard (Diagnose-HFpEF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with&#xD;
      unexplained dyspnea NYHA II-III compared to other diagnostic tools&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple diagnostic tests, including stress tests and the invasive conduction of left&#xD;
      ventricular pressure-volume loops via conductance catheter (as gold standard) will be&#xD;
      performed in patients with unexplained dyspnea NYHA II-III in order to identify patients with&#xD;
      a heart failure with preserved ejection fraction (HFpEF). The results will be compared to&#xD;
      previously reported diagnostic scores such as the H2FPEF and the HFA-PEFF score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HFpEF-positive patients</measure>
    <time_frame>Within one day</time_frame>
    <description>Percentage of patients with invasively diagnosed heart failure with preserved ejection fraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>H2FPEF score</measure>
    <time_frame>Within two days</time_frame>
    <description>Difference in H2FPEF score in patients with approved and excluded HFpEF (BMI &gt; 30 kg/m²: 2 points, 2 or more antihypertensive medicines: 1 point, atrial fibrillation: 3 points, pulmonary hypertension: 1 point, age &gt; 60 years: 1 point, E/E' &gt; 9: 1 point. Sum: 0-9 points with rising probability of HFpEF with increasing score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HFA-PEFF score</measure>
    <time_frame>Within two days</time_frame>
    <description>Difference in HFA-PEFF score in patients with approved and excluded HFpEF (0-2 points regarding functional, morpholigical and biomarker parameters. Sum: 0-6 points; 0-1 points:exclusion of HFpEF, 2-5 points: further diagnostic (stress test or invasive) required, 5-6 points: HFpEF diagnosed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in DPVQ (echocardiographic)</measure>
    <time_frame>Within two days</time_frame>
    <description>Diastolic pressure-volume quotient (DPVQ) (at rest and under exertion) in patients with approved and excluded HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in E/E' (echocardiographic)</measure>
    <time_frame>Within two days</time_frame>
    <description>E/E' (at rest and under exertion) in patients with approved and excluded HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in GLS (echocardiographic)</measure>
    <time_frame>Within two days</time_frame>
    <description>Global longitudinal strain (at rest and under exertion) in patients with approved and excluded HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in MRI parameters</measure>
    <time_frame>Within two days</time_frame>
    <description>Fibrosis (using late gadolinium enhancement and T1-Mapping) in patients with approved and excluded HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in pulmonary artery pressure (right heart catheter)</measure>
    <time_frame>Within two days</time_frame>
    <description>Pulmonary artery pressure at rest and under exertion in patients with approved and excluded HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in wedge pressure (right heart catheter)</measure>
    <time_frame>Within two days</time_frame>
    <description>Wedge pressure at rest and under exertion in patients with approved and excluded HFpEF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in DPVQ (echocardiographic) after one year</measure>
    <time_frame>1 year</time_frame>
    <description>Diastolic pressure-volume quotient (DPVQ) at rest in patients with approved and excluded HFpEF after one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in E/E' (echocardiographic) after one year</measure>
    <time_frame>1 year</time_frame>
    <description>E/E' at rest in patients with approved and excluded HFpEF after one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in GLS (echocardiographic) after one year</measure>
    <time_frame>1 year</time_frame>
    <description>Global longitudinal strain at rest in patients with approved and excluded HFpEF after one year</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Dyspnea explained by heart failure with preserved ejection fraction</arm_group_label>
    <description>All patients fulfilling invasive criteria for heart failure with preserved ejection fraction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dyspnea not explained by heart failure with preserved ejection fraction</arm_group_label>
    <description>All patients not fulfilling invasive criteria for heart failure with preserved ejection fraction</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Invasive hemodynamics of left ventricle via conductance catheter at rest, with exercise and with temporary vena cava occlusion</intervention_name>
    <description>Invasive hemodynamics of left ventricle will be done by the conductance method. Left ventricular stiffness constant will be obtained by temporary vena cava occlusion. Right heart catherization will be done by pulmonary artery catherization and cardiac output will be estimated by thermodilution and Fick´s method.</description>
    <arm_group_label>Dyspnea explained by heart failure with preserved ejection fraction</arm_group_label>
    <arm_group_label>Dyspnea not explained by heart failure with preserved ejection fraction</arm_group_label>
    <other_name>Cardiac MRI at rest</other_name>
    <other_name>Echocardiography at rest and with exercise</other_name>
    <other_name>Spiroergometry</other_name>
    <other_name>6 minute walking distance</other_name>
    <other_name>Right heart catherization at rest and with exercise</other_name>
    <other_name>Coronary angiography (if not performed within the last year)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Approximately 40 ml of blood will be drawn for the conduction of hemogram, sodium, potassium,&#xD;
      creatine, eGFR, urea, coagulation, TSH, CK, high-sensitivity troponin T, NT-proBNP, HbA1c,&#xD;
      lipids, iron status as well as biobanking (at -80°C) for 15 years.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with unexplained dyspnea NYHA II-III&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  dyspnea NYHA II-III&#xD;
&#xD;
          -  age 18-90 years&#xD;
&#xD;
          -  left ventricular ejection fraction ≥ 50%&#xD;
&#xD;
          -  ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unstable cardiac disease with acute decompensation&#xD;
&#xD;
          -  documented former LVEF ≤ 40%&#xD;
&#xD;
          -  heart valve disease with medium or high grade insufficiency or stenosis&#xD;
&#xD;
          -  coronary heart disease with hemodynamically relevant coronary stenosis&#xD;
&#xD;
          -  specific cardiomyopathia&#xD;
&#xD;
          -  acute or chronic cardiac inflammation (myocarditis, pericarditis)&#xD;
&#xD;
          -  former heart transplantation&#xD;
&#xD;
          -  relevant pulmonary disease (e.g. COPD) assumably causing the dyspnea&#xD;
&#xD;
          -  FEV1/VC &lt; 70%&#xD;
&#xD;
          -  hemoglobin &lt; 5 mmol/l&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
&#xD;
          -  contraindication for one of the diagnostic tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rolf Wachter, MD</last_name>
    <phone>+49-341-97-12825</phone>
    <email>rolf.wachter@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romy Langhammer, MD</last_name>
    <phone>+49-341-97-20523</phone>
    <email>romy.langhammer@medizin.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Wachter, MD</last_name>
      <phone>+49-341-97-12825</phone>
      <email>rolf.wachter@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Romy Langhammer, MD</last_name>
      <phone>+49-341-97-20523</phone>
      <email>romy.langhammer@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Rolf Wachter</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Available upon reasonable scientific request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

